Pharmacokinetics and immunological outcomes of alemtuzumab-based treatment for steroid-refractory acute GvHD

Bone Marrow Transplant. 2016 Aug;51(8):1153-5. doi: 10.1038/bmt.2016.83. Epub 2016 Apr 4.

Authors

S-K Tey^{1

2}, S Vuckovic¹, A Varelias¹, J P Martins¹, S Olver¹, L Samson¹, E Sturgeon², J Leach², J Avery², M Nakagaki², J P Butler², C Curley², A J Morton², S T Durrant², G A Kennedy^{1

2}, G R Hill^{1

2}

Affiliations

¹ Bone Marrow Transplant Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
² Department of Haematology and Bone Marrow Transplantation, Royal Brisbane and Women's Hospital, Butterfield St, Brisbane, Queensland, Australia.

PMID: 27042838
DOI: 10.1038/bmt.2016.83

No abstract available

Publication types

Clinical Trial, Phase II
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Acute Disease
Adult
Aged
Alemtuzumab / immunology
Alemtuzumab / pharmacokinetics
Alemtuzumab / therapeutic use*
Female
Graft vs Host Disease / drug therapy*
Humans
Lymphocyte Depletion
Male
Middle Aged
Salvage Therapy / methods*
Steroids / pharmacology
Treatment Outcome

Substances

Steroids
Alemtuzumab